AdvisorShares Pure US Cannabis ETF

Trump's Executive Order Prompts U.S. Cannabis Policy Changes, Boosting Market Sentiment

US Justice Department Reschedules Marijuana to Schedule III

Trump May Re-Classify Marijuana Regulatory Status

SynBiotic SE Announces Strategy for the Developing Cannabis Market

Pure US Cannabis ETF (IIP) Releases Q2 Performance

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

TCNNF

TLRY

CURLF

CRON

GTBIF

MSOS

A new report from the Global Cannabis Network Collective and Whitney Economics highlights pricing compression as a key indicator of cannabis market maturity. It analyzes how expanding supply and evolving regulations impact pricing across emerging markets in Europe and Latin America. The report emphasizes that while initial market prices may be high, sustained downward pressure is common as markets mature. It also discusses the influence of regulatory frameworks and consumer behavior on pricing stability and operator profitability, providing insights for investors and policymakers.

prnewswire

Trulieve Cannabis Corp.

Tilray Brands

Aurora Cannabis

Curaleaf Holdings, Inc.

Canopy Growth

Cronos

Green Thumb Industries Inc.

Amplify Alternative Harvest ETF

07:05 ETNew Global Cannabis Report from GCNC and Whitney Economics Examines How Pricing Compression Reshapes Emerging Markets

CRLBF

IIPR

VICE

The recent rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act marks a significant regulatory shift for the U.S. cannabis industry. CEOs from major cannabis companies highlight key implications for investors, including improved cash flow, better access to banking services, potential uplisting on exchanges, and increased interest from institutional investors. However, there are concerns about overly optimistic timelines for recreational cannabis rescheduling, as support for such changes remains limited.

CabotWealthNetwork

Cresco Labs Inc.

Innovative Industrial Properties

AdvisorShares Vice - ETF

Here’s What “Rescheduling” Really Means for Investors

Curaleaf Holdings, Inc. has announced the replacement of its independent auditor PKF O’Connor Davies with BDO USA, effective May 6, 2026. This change follows an unqualified audit history, indicating it is a routine governance step rather than a response to any accounting issues. The transition is documented under Canadian continuous disclosure rules, emphasizing continuity in financial oversight. Analysts rate CURA stock as a Buy with a C$5.00 price target, while Spark's AI Analyst gives it a Neutral rating due to ongoing net losses and leverage concerns.

Tip Ranks

Curaleaf Replaces PKF O’Connor Davies with BDO USA as Independent Auditor

Curaleaf Holdings has opened two new medical dispensaries in Jacksonville Beach and Fernandina Beach, increasing its Florida locations to 73 and total nationwide stores to 165. CEO Boris Jordan stated that this expansion aligns with their strategy to enhance their presence in the medical cannabis market, allowing for better localized product offerings and patient-focused services across Florida.

fidelity

Curaleaf Holdings Opens Two New Stores in Florida

Curaleaf Bolsters Florida Footprint with Two New Medical Dispensaries in Jacksonville Beach and Fernandina Beach | CURLF Stock News

StockTitan

Curaleaf Bolsters Florida Footprint with Two New Medical Dispensaries in Jacksonville Beach and Fernandina Beach | CURLF Stock News

Companies selling recreational marijuana in Illinois and Connecticut are facing lawsuits for allegedly failing to warn consumers about health risks associated with the drug. The lawsuits, filed on May 4, claim that cannabis can lead to serious health issues, including addiction and mental health disorders. Plaintiffs seek damages and clearer product warnings. The defendants, including Cresco and Curaleaf, deny the allegations, asserting compliance with state laws and regulations. The lawsuits highlight concerns over the marketing of marijuana products without adequate risk disclosures.

ZeroHedge

Marijuana Vendors Sued For Allegedly Not Warning Consumers Of Risks

CNBS

The AdvisorShares Pure US Cannabis ETF (MSOS) has seen a significant increase of 31% in one month and 69% over the past year, largely due to its holdings in US multi-state operators benefiting from potential Section 280E tax relief if cannabis rescheduling occurs. The Amplify Seymour Cannabis ETF (CNBS) provides diversified exposure to the US cannabis market.

Amplify Seymour Cannabis ETF

Cannabis rescheduling could unlock the biggest MSO rally since 2021

Curaleaf Holdings, Inc. filed a Form 6-K with the SEC, reporting unaudited interim financials for Q1 2026. The filing includes financial statements as of March 31, 2026, and management's analysis, ensuring compliance and transparency. The latest analyst rating for CURA stock is a Buy with a C$5.50 price target, while Spark's AI Analyst rates it as Neutral, citing improving cash flow but weak underlying profitability. Curaleaf operates in the cannabis sector, registered with the SEC, and has a market cap of C$3.45B.

Curaleaf Files Q1 2026 Interim Financials on Form 6-K

A series of federal lawsuits have been filed against major cannabis companies, including Cresco Labs and Curaleaf, accusing them of misleading consumers about the medicinal benefits of their products. The lawsuits allege that these companies marketed cannabis as a treatment for various conditions despite knowing the scientific evidence was weak or nonexistent. Concurrently, the European Food Safety Authority has stated it cannot confirm the safety of CBD, while the U.S. government plans to include these products in Medicare without FDA approval, raising significant concerns about public health and safety.

MorningStar

Big Cannabis Sold You a Lie. Now the Federal Government Is Giving It to Your Grandparents.

SHOP

The TSX Composite Index fell 71.06 points to 33,566.91, influenced by a drop in Shopify shares, which fell 15.6%. TMX Group reported better-than-expected earnings, while Dream Impact Trust's losses widened. Health-care stocks rose, with Curaleaf and Bausch Health gaining. The TSX Venture Exchange also declined. In the U.S., stocks surged, with the Dow up 356.63 points and the NASDAQ hitting an all-time high. Oil prices dropped, while gold prices increased significantly. Overall, 85% of S&P 500 companies exceeded earnings expectations.

AdvisorShares Pure US Cannabis ETF(MSOS.US)

07:05 ETNew Global Cannabis Report from GCNC and Whitney Economics Examines How Pricing Compression Reshapes Emerging Markets

Here’s What “Rescheduling” Really Means for Investors

Curaleaf Replaces PKF O’Connor Davies with BDO USA as Independent Auditor

Curaleaf Holdings Opens Two New Stores in Florida

Curaleaf Bolsters Florida Footprint with Two New Medical Dispensaries in Jacksonville Beach and Fernandina Beach | CURLF Stock News

Marijuana Vendors Sued For Allegedly Not Warning Consumers Of Risks

Cannabis rescheduling could unlock the biggest MSO rally since 2021

Curaleaf Files Q1 2026 Interim Financials on Form 6-K

Big Cannabis Sold You a Lie. Now the Federal Government Is Giving It to Your Grandparents.

TSX Staggers by Tuesday Finish